| Dr Danielle M Adams, MD | |
|
900 Round Valley Dr, Suite 200, Park City, UT 84060-7552 | |
| (435) 658-7400 | |
| (435) 658-7401 |
| Full Name | Dr Danielle M Adams |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 20 Years |
| Location | 900 Round Valley Dr, Park City, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699957886 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 6020572-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Park City Hospital | Park city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain.
This debate will centre around why humans are constantly under attack from infectious diseases such as E.coli despite medical advances in vaccinations and antibiotics, and how micro-organisms that cause disease evolve and adapt quickly to the many barriers that our bodies' anti-infection strategies and our drugs industry throw at them.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML).
› Verified 6 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain.
This debate will centre around why humans are constantly under attack from infectious diseases such as E.coli despite medical advances in vaccinations and antibiotics, and how micro-organisms that cause disease evolve and adapt quickly to the many barriers that our bodies' anti-infection strategies and our drugs industry throw at them.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML).
› Verified 6 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain.
This debate will centre around why humans are constantly under attack from infectious diseases such as E.coli despite medical advances in vaccinations and antibiotics, and how micro-organisms that cause disease evolve and adapt quickly to the many barriers that our bodies' anti-infection strategies and our drugs industry throw at them.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Danielle M Adams, MD Po Box 30180, Suite 200, Salt Lake City, UT 84130-0180 Ph: (801) 419-3213 | Dr Danielle M Adams, MD 900 Round Valley Dr, Suite 200, Park City, UT 84060-7552 Ph: (435) 658-7400 |
News Archive
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain.
This debate will centre around why humans are constantly under attack from infectious diseases such as E.coli despite medical advances in vaccinations and antibiotics, and how micro-organisms that cause disease evolve and adapt quickly to the many barriers that our bodies' anti-infection strategies and our drugs industry throw at them.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML).
› Verified 6 days ago
Mrs. Vanessa Marie Hart, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 900 Round Valley Dr, Ste. 200, Park City, UT 84060 Phone: 435-658-7400 | |
Katherine Elizabeth Smiley, Surgery Medicare: Accepting Medicare Assignments Practice Location: 900 Round Valley Dr Ste 200, Park City, UT 84060 Phone: 435-658-7400 | |
Dr. Terry K Clark, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 4976 E Meadows Dr, Park City, UT 84098 Phone: 435-602-9767 Fax: 413-683-9923 | |
Dr. Jesse Perry, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 777 Old Ranch Rd, Park City, UT 84098 Phone: 435-647-5900 |